Thomas E. Nelson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas E. Nelson has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Astrid de Bantel
Barrow Neurological Institute, Phoenix; and 2Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC
1 shared publicationHenry Rosenberg
Department of Medical Education, Saint Barnabas Medical Center, Livingston, New Jersey; Malignant Hyperthermia Association of the United States, Sherburne, New York
1 shared publicationKumaraswamy Sivakumar
Barrow Neurological Institute, Phoenix; and 2Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC
1 shared publicationNyamkhishig Sambuughin
Barrow Neurological Institute, Phoenix; and 2Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC
1 shared publicationSheila M. Muldoon
Department of Anesthesiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland
1 shared publicationShona McWilliams
Barrow Neurological Institute, Phoenix; and 2Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC
1 shared publication
Latest Publications
- 1 February 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 100 (2) , 212-214
Genetic Testing for Malignant Hyperthermia in North America
- 1 February 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 100 (2) , 212-214
Genetic Testing for Malignant Hyperthermia in North America
- 1 June 2002
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 2 (4) , 347-369
Malignant Hyperthermia: A Pharmacogenetic Disease of Ca++ Regulating Proteins
Malignant hyperthermia (MH) is a pharmacogenetic, life-threatening hypermetabolic syndrome in genetically predisposed individuals exposed to certain anesthetic agents. Discovered by Denborough and Lovell [1] in 1960, MH was associated with high mortality and morbidity as the cause was unknown and an effective treatment was unavailable. There is no classic clinical presentation of the syndrome, and the onset and signs of MH are dependent upon known and unknown environmental and genetic factors. Initial theories involved central temperature regulation defects or uncoupling of oxidative phosphorylation in mitochondria [2], but later investigations targeted skeletal muscle as the affected organ. Subsequently freshly biopsied skeletal muscle was used for in vitro pharmacologic contracture testing to discriminate between normal and MH-affected muscle and remains the “gold standard” for MH diagnosis. Spontaneous, genetic models for MH were discovered in pigs and dogs and substantial knowledge about MH was gained from these valuable resources. The abnormal contracture response of MH skeletal muscle evoked a focus on calcium regulation, and abnormalities in calcium release (as opposed to calcium sequestration) mechanisms were discovered. About this same time the major calcium release channel in the skeletal muscle sarcoplasmic reticulum membrane was purified and named the ryanodine receptor [3]. Although the ryanodine receptor represents one of the largest functional proteins, the enormous gene encoding the 5021 amino acids comprising the ryanodine receptor subunit was eventually cloned [4,5]. Patient and dedicated work on the ryanodine receptor gene has found linkage to MH in the pig [6], dog [7], and among several different mutations and MH in unrelated human families [8,9]. Expression of these mutations in HEK cells has resulted in abnormal calcium release [10,11], supporting but not proving a causal basis for MH. In this review each of the areas mentioned above is discussed in detail revealing a wonderful success story that changed the anesthesiologists “worst nightmare” from a syndrome with high mortality and morbidity to a reasonably well managed disease today. This success story includes unraveling the molecular basis for the disease and brings its pathoetiologic and diagnostic aspects toward molecular genetic resolution.
- 1 June 2002
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 2 (4) , 347-369
Malignant Hyperthermia: A Pharmacogenetic Disease of Ca++ Regulating Proteins
Malignant hyperthermia (MH) is a pharmacogenetic, life-threatening hypermetabolic syndrome in genetically predisposed individuals exposed to certain anesthetic agents. Discovered by Denborough and Lovell [1] in 1960, MH was associated with high mortality and morbidity as the cause was unknown and an effective treatment was unavailable. There is no classic clinical presentation of the syndrome, and the onset and signs of MH are dependent upon known and unknown environmental and genetic factors. Initial theories involved central temperature regulation defects or uncoupling of oxidative phosphorylation in mitochondria [2], but later investigations targeted skeletal muscle as the affected organ. Subsequently freshly biopsied skeletal muscle was used for in vitro pharmacologic contracture testing to discriminate between normal and MH-affected muscle and remains the “gold standard” for MH diagnosis. Spontaneous, genetic models for MH were discovered in pigs and dogs and substantial knowledge about MH was gained from these valuable resources. The abnormal contracture response of MH skeletal muscle evoked a focus on calcium regulation, and abnormalities in calcium release (as opposed to calcium sequestration) mechanisms were discovered. About this same time the major calcium release channel in the skeletal muscle sarcoplasmic reticulum membrane was purified and named the ryanodine receptor [3]. Although the ryanodine receptor represents one of the largest functional proteins, the enormous gene encoding the 5021 amino acids comprising the ryanodine receptor subunit was eventually cloned [4,5]. Patient and dedicated work on the ryanodine receptor gene has found linkage to MH in the pig [6], dog [7], and among several different mutations and MH in unrelated human families [8,9]. Expression of these mutations in HEK cells has resulted in abnormal calcium release [10,11], supporting but not proving a causal basis for MH. In this review each of the areas mentioned above is discussed in detail revealing a wonderful success story that changed the anesthesiologists “worst nightmare” from a syndrome with high mortality and morbidity to a reasonably well managed disease today. This success story includes unraveling the molecular basis for the disease and brings its pathoetiologic and diagnostic aspects toward molecular genetic resolution.
- 1 July 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 69 (1) , 204-208
Single-Amino-Acid Deletion in the RYR1 Gene, Associated with Malignant Hyperthermia Susceptibility and Unusual Contraction Phenotype
- 1 July 2001
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 69 (1) , 204-208
Single-Amino-Acid Deletion in the RYR1 Gene, Associated with Malignant Hyperthermia Susceptibility and Unusual Contraction Phenotype
- 1 April 2001
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 21 (2) , 169-179
Heat Production During Anesthetic-Induced Malignant Hyperthermia
Malignant hyperthermia (MH) is a pharmacogenetic disease which predisposes to the trigger of a life-threatening, hypermetabolic syndrome by potent inhaled anesthetics and by depolarizing skeletal muscle relaxants. Heat production in the anesthetized MH can be profound with 5-fold increases in oxygen consumption. The trigger anesthetics cause an abnormal, sustained rise in myoplasmic calcium levels. Possible mechanisms by which continuous release of calcium from skeletal muscle sarcoplasmic reticulum stores can produce the profound hyperthermia are discussed. Mutations in the gene coding the ryanodine receptor calcium release channel have been found in MH families and these mutant channels may be the functionsl basis for MH.
- 1 April 2001
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 21 (2) , 169-179
Heat Production During Anesthetic-Induced Malignant Hyperthermia
Malignant hyperthermia (MH) is a pharmacogenetic disease which predisposes to the trigger of a life-threatening, hypermetabolic syndrome by potent inhaled anesthetics and by depolarizing skeletal muscle relaxants. Heat production in the anesthetized MH can be profound with 5-fold increases in oxygen consumption. The trigger anesthetics cause an abnormal, sustained rise in myoplasmic calcium levels. Possible mechanisms by which continuous release of calcium from skeletal muscle sarcoplasmic reticulum stores can produce the profound hyperthermia are discussed. Mutations in the gene coding the ryanodine receptor calcium release channel have been found in MH families and these mutant channels may be the functionsl basis for MH.